• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Unproven (Off-Label) Treatments

Unproven (Off-Label) Treatments

Background

Given the lack of approved and effective treatments for ALS, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety and in all of them; there is no proof of benefit. Furthermore, these treatments are often extremely expensive, capitalizing on desperation and hope, and many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Examples of such treatments include, but are not limited to; stem cell clinics, holistic/naturopathic/homeopathic/traditional medicine, and dietary or physical therapy regimens.

Resources like ALSUntangled (www.alsuntangled.com) can be valuable for balanced, open-access information about such alternative treatments and www.clinicaltrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

A forthcoming ALSUntangled podcast/review entitled ‘“ten red flags”-things to be wary of in alternative or off-label products’ provides helpful guide to the warning signs to look out for in an advertised potential treatment. Click here for the “ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved/unproven/off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like www.clinicaltrials.gov are encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there was anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

 

International Alliance of ALS/MND Associations
June 2020

 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Jon Newsome, USA

    Jon Newsome, USA

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Daniel Hare, USA

    Daniel Hare, USA

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Purningam Jacob, India

    Purningam Jacob, India

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Hollister

    Hollister
    hollister

  • Alex, Argentina

    Alex, Argentina

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Mark Miller, UK

    Mark Miller, UK

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Jose Rivero Muñoz, Mexico

    Jose Rivero Muñoz, Mexico

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Paul Launer, USA

    Paul Launer, USA

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Anna Barrow, UK

    Anna Barrow, UK

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login